Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price of a new drug has never been more important. To help them decide on the all-important list price, some of the world’s top pharmaceutical companies have a well-kept secret.

Model N may not be a household name just yet, but it’s working with 70% of the top 25 pharma companies in the world and seven of the top 10, as well as countless emerging companies. A software company which provides revenue management solutions to life sciences companies, Model N links together and automates the complexities of developing and executing pricing, contracts, incentives and regulatory compliance throughout a product’s life cycle. The aim is to help companies manage financial risk and regulatory exposure in the most effective way possible.

Founded in 1999, Model N has its headquarters in the world’s most exciting development space, Silicon Valley in San Francisco, California, but it has offices across the USA and around the world in London, India and Switzerland. The Pharma Letter spoke to Arnaud Grunwald (pictured), Model N’s director of global pricing about how it can help pharma companies protect their revenue.